What is Heligenics?
Heligenics operates at the intersection of advanced diagnostics and therapeutic innovation. The company distinguishes itself through its proprietary GigaAssay technology, a high-content screening platform designed to map the functional impact of genetic variations across extensive biologic libraries. This technical infrastructure allows Heligenics to streamline the discovery of next-generation insulin and antibody therapies. By providing pharmaceutical partners with high-value, validated biologic assets, the firm effectively reduces the risk and duration of the early-stage drug discovery process, positioning itself as a critical service provider in the global biotech ecosystem.
How much funding has Heligenics raised?
Heligenics has raised a total of $41K across 1 funding round:
Debt
$41K
Debt (2021): $41K with participation from PPP
Key Investors in Heligenics
PPP
Public-Private Partnership
What's next for Heligenics?
With the recent influx of capital, Heligenics is well-positioned to scale its operational capacity and expand its portfolio of licensed biologic assets. The strategic focus will likely shift toward deepening partnerships with major pharmaceutical entities and enhancing the throughput of the GigaAssay platform. As the industry moves toward more personalized and precise biologic interventions, Heligenics' ability to provide granular data on genetic variants will be a key driver of its long-term growth. The company is currently navigating a critical growth phase, transitioning from a specialized research entity to a foundational partner in the global drug discovery value chain.
See full Heligenics company page
